In a series of 2020 reviews, Unquote dives into the data to discover how the various regions of Europe performed during the coronavirus crisis, and what GPs expect for the year ahead.
The full picture of Covid-19's impact on private equity activity will become clearer when final numbers can be tallied up in early 2021. But the early figures highlight how a 2008-style meltdown was averted, both in terms of deal-doing and fundraising.
That said, the crisis has further exacerbated a bifurcation in the market that is likely to lead to ever more competitive processes and correspondingly high average entry multiples, at a time when the full ramifications of Covid-19 for a number of businesses are still not crystal clear.
Unquote editor Greg Gille welcomes Unquote's UK market specialist, Katharine Hidalgo, to discuss how the UK industry fared in 2020, and what's on the minds of market players as 2021 beckons.
0:00 – Intro
0:33 – Pan-European 2020 trends overview
2:38 – UK headline figures
4:50 – Pent-up demand and CGT hike looming
9:14 – Outlook for 2021
Theme music: ©2012 Kick Up The Fire
Arcus could increase its share to a majority stake in future, the GP said in a statement
Finnish venture capitla firm Maki.vc has led a €1.5m funding round for Helsinki-based financial analytics provider Calqulate.
Advanz Pharma initially hired Jefferies to advise on a sale process in October 2020
Company has also received €1.4m in venture loans and soft money from the Danish Growth Fund and Innovation Fund Denmark